| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2011 | CA2770066A1 Composition for the treatment of cystic fibrosis |
| 02/10/2011 | CA2770023A1 Treatment of macrophage-related disorders |
| 02/10/2011 | CA2769977A1 Benzylpiperidine compound |
| 02/10/2011 | CA2769665A1 Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
| 02/10/2011 | CA2769652A1 Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| 02/10/2011 | CA2769620A1 Orally administerable pharmaceutical preparation containing insulin |
| 02/10/2011 | CA2769563A1 Novel compounds as modulators of glucocorticoid receptors |
| 02/10/2011 | CA2769421A1 Viral replication inhibitors |
| 02/10/2011 | CA2769199A1 Pesticidal compositions |
| 02/10/2011 | CA2769124A1 Conformationally constrained, fully synthetic macrocyclic compounds |
| 02/10/2011 | CA2768858A1 Bicyclic aryl sphingosine 1-phosphate analogs |
| 02/10/2011 | CA2768638A1 Bis-benzimidazole derivatives as hepatitis c virus inhibitors |
| 02/10/2011 | CA2768637A1 Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
| 02/10/2011 | CA2768632A1 Process for the manufacture of pharmaceutically active compounds |
| 02/10/2011 | CA2768587A1 Dp2 antagonist and uses thereof |
| 02/10/2011 | CA2768553A1 Anhydrate of tiotropium bromide |
| 02/10/2011 | CA2768543A1 Compositions and methods for inhibition of the jak pathway |
| 02/10/2011 | CA2768425A1 Controlled-release granular compositions containing mesalazine and process for the manufacture thereof |
| 02/10/2011 | CA2768195A1 Lipidated oxoadenine derivatives |
| 02/10/2011 | CA2768043A1 Cyclopropyl modulators of p2y12 receptor |
| 02/10/2011 | CA2768041A1 Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents |
| 02/10/2011 | CA2764577A1 Method of preventing renal disease and treating symptoms thereof |
| 02/10/2011 | CA2763956A1 Metabotropic glutamate receptor modulators |
| 02/10/2011 | CA2760177A1 Food formulation comprising glycogen |
| 02/09/2011 | EP2281901A2 Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| 02/09/2011 | EP2281896A2 Transgenic plant-based methods for plant insect pests using RNAi |
| 02/09/2011 | EP2281885A1 Combination therapy for the treatment of ocular neovascular disorders |
| 02/09/2011 | EP2281876A2 Methods for controlling pests using RNAi |
| 02/09/2011 | EP2281841A2 Biomarkers for pre-selection of patients for anti-IGF1R therapy |
| 02/09/2011 | EP2281824A1 Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 02/09/2011 | EP2281823A2 Anti-inflammatory and analgesic piperidine derivatives |
| 02/09/2011 | EP2281822A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them |
| 02/09/2011 | EP2281821A1 Process for producing crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole |
| 02/09/2011 | EP2281819A1 Benzimidazolyl or benzoxazolyl derivatives |
| 02/09/2011 | EP2281818A1 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2011 | EP2281817A1 Substituted carbinol compound having cyclic linker |
| 02/09/2011 | EP2281815A1 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid ethyl ester intermediate compound |
| 02/09/2011 | EP2281813A1 Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| 02/09/2011 | EP2281566A1 Synergic 5'-methylthioadenosine combinations |
| 02/09/2011 | EP2281565A2 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same |
| 02/09/2011 | EP2281564A2 Derivatives of prostaglandins for treating abdominal discomfort |
| 02/09/2011 | EP2281563A1 2,4-Pyrimidinediamine compounds and their uses |
| 02/09/2011 | EP2281562A2 Method of bowel cleansing |
| 02/09/2011 | EP2281561A2 Use of LCK inhibitors for treatment of immunologic diseases |
| 02/09/2011 | EP2281560A1 Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomatous optic neuropathy |
| 02/09/2011 | EP2281559A1 Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| 02/09/2011 | EP2281558A1 Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors |
| 02/09/2011 | EP2281555A2 Once-a-day oxycodone formulations |
| 02/09/2011 | EP2281554A1 Eye drop composition comprising ketotifen |
| 02/09/2011 | EP2281553A2 Pharmaceutical composition and method for treating hypogonadism |
| 02/09/2011 | EP2281058A1 Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
| 02/09/2011 | EP2281047A1 Methods to produce rod-derived cone viability factor (rdcvf) |
| 02/09/2011 | EP2281043A2 Improved tlr3 agonist compositions |
| 02/09/2011 | EP2281008A2 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof |
| 02/09/2011 | EP2281001A1 Anti-areg/hb-egf antibodies and treatment |
| 02/09/2011 | EP2280987A2 Triterpene saponins, methods of synthesis, and uses thereof |
| 02/09/2011 | EP2280986A2 Synthetic analogues of phosphatidyl-myo-inositol mannosides with an inhibitory activity on the inflammatory response |
| 02/09/2011 | EP2280985A2 Use of mannose-6-phosphate for controlling angiogenesis, ligament regeneration, and cartilage reconstruction |
| 02/09/2011 | EP2280984A2 Sulfated galactans with antithrombotic activity, pharmaceutical composition, method for treating or prophylaxis of arterial or venous thrombosis, method of extraction and use thereof |
| 02/09/2011 | EP2280983A2 C-aryl glycoside compounds for the treatment of diabetes and obesity |
| 02/09/2011 | EP2280982A1 Thiazolyl-dihydro-indazoles |
| 02/09/2011 | EP2280981A1 Bridged heterocycles as hiv integrase inhibitors |
| 02/09/2011 | EP2280980A1 Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate |
| 02/09/2011 | EP2280978A1 Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| 02/09/2011 | EP2280976A1 Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines as gsk3beta-inhibitors |
| 02/09/2011 | EP2280975A1 7h-indoloý2,1-a¨ý2¨benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c |
| 02/09/2011 | EP2280973A1 Carba-nucleoside analogs for antiviral treatment |
| 02/09/2011 | EP2280970A1 Imidazolidinone derivatives as 11b-hsd1 inhibitors |
| 02/09/2011 | EP2280968A2 Pyrido [3, 4-b]indoles and methods of use |
| 02/09/2011 | EP2280967A2 Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity |
| 02/09/2011 | EP2280966A1 Azabicyclo [3.2.1]octyl derivatives as 11 beta-hsd1 modulators |
| 02/09/2011 | EP2280964A1 Chlorothiophene-isoxazoles as inhibitors of coagulation factors xa and thrombin |
| 02/09/2011 | EP2280962A1 Pyridazinone derivatives |
| 02/09/2011 | EP2280961A1 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands |
| 02/09/2011 | EP2280959A1 Novel compounds |
| 02/09/2011 | EP2280958A1 Hepatitis c virus inhibitors |
| 02/09/2011 | EP2280957A1 Pyridine derivatives used to treat orexin related disorders |
| 02/09/2011 | EP2280955A2 Crystalline form of 6-ý(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl¨pyridazin-3-amine |
| 02/09/2011 | EP2280954A1 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase cyp11b2 |
| 02/09/2011 | EP2280953A1 New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| 02/09/2011 | EP2280951A2 Processes for the preparation of benzo-fused dioxin derivatives |
| 02/09/2011 | EP2280950A1 Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide |
| 02/09/2011 | EP2280948A1 Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers. |
| 02/09/2011 | EP2280946A1 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| 02/09/2011 | EP2280945A1 Trisubstituted pyrazoles as acetylcholine receptor modulators |
| 02/09/2011 | EP2280943A1 New substituted spiroýcycloalkyl-1,3'-indol¨-2'(1'h)-one derivatives and their use as p38 mitogen-activated kinase inhibitors. |
| 02/09/2011 | EP2280941A1 (hetero-)aryl cyclohexane derivatives |
| 02/09/2011 | EP2280940A1 Novel n-(2-amino-phenyl)-acrylamides |
| 02/09/2011 | EP2280935A1 4-trimethylammonio-butyrates as cpt2 inhibitors |
| 02/09/2011 | EP2280934A2 Fatty acid amides and uses thereof |
| 02/09/2011 | EP2280933A1 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| 02/09/2011 | EP2280930A1 A novel and efficient method for the synthesis of an amino acid |
| 02/09/2011 | EP2280928A2 Vinyl substituted fatty acids |
| 02/09/2011 | EP2280927A1 Nitrated hydrocarbons, derivatives, and processes for their manufacture |
| 02/09/2011 | EP2280915A1 Novel ýf-18¨-labelled l-glutamic acid and l-glutamine derivatives (ii), use thereof and method for their production |
| 02/09/2011 | EP2280766A1 Carboxamide compounds and their use as chemokine receptor agonists |
| 02/09/2011 | EP2280742A2 Medical devices, polymers, compositions, and methods for delivering a haloacetate |
| 02/09/2011 | EP2280733A1 Maintenance therapy regimen for treating acne |
| 02/09/2011 | EP2280714A1 Compositions comprising anrnox-inhibitors for the inhibition of reactive oxygen species |
| 02/09/2011 | EP2280713A1 Methods and kits for the treatment of inflammatory bowel disorder conditions |